25 XP   0   0   10

Pharma Mar SAU
Buy, Hold or Sell?

Let's analyse Pharma Mar SAU together

PenkeI guess you are interested in Pharma Mar SAU. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharma Mar SAU. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pharma Mar SAU

I send you an email if I find something interesting about Pharma Mar SAU.

Quick analysis of Pharma Mar SAU (30 sec.)










What can you expect buying and holding a share of Pharma Mar SAU? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
33.3%

What is your share worth?

Current worth
€10.97
Expected worth in 1 year
€9.62
How sure are you?
66.7%

+ What do you gain per year?

Total Gains per Share
€-1.35
Return On Investment
-4.8%

For what price can you sell your share?

Current Price per Share
€28.22
Expected price per share
€0 - €29.44
How sure are you?
50%

1. Valuation of Pharma Mar SAU (5 min.)




Live pricePrice per Share (EOD)

€28.22

Intrinsic Value Per Share

€-42.78 - €-51.68

Total Value Per Share

€-31.81 - €-40.72

2. Growth of Pharma Mar SAU (5 min.)




Is Pharma Mar SAU growing?

Current yearPrevious yearGrowGrow %
How rich?$207m$225.8m-$4.6m-2.1%

How much money is Pharma Mar SAU making?

Current yearPrevious yearGrowGrow %
Making money$304.2k$13.2m-$12.9m-4,240.9%
Net Profit Margin0.6%25.0%--

How much money comes from the company's main activities?

3. Financial Health of Pharma Mar SAU (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#246 / 1010

Most Revenue
#163 / 1010

Most Profit
#155 / 1010

Most Efficient
#157 / 1010

What can you expect buying and holding a share of Pharma Mar SAU? (5 min.)

Welcome investor! Pharma Mar SAU's management wants to use your money to grow the business. In return you get a share of Pharma Mar SAU.

What can you expect buying and holding a share of Pharma Mar SAU?

First you should know what it really means to hold a share of Pharma Mar SAU. And how you can make/lose money.

Speculation

The Price per Share of Pharma Mar SAU is €28.22. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharma Mar SAU.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharma Mar SAU, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €10.97. Based on the TTM, the Book Value Change Per Share is €-0.34 per quarter. Based on the YOY, the Book Value Change Per Share is €0.61 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharma Mar SAU.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.41-1.5%0.020.1%0.702.5%0.943.3%0.943.3%
Usd Book Value Change Per Share-0.67-2.4%-0.36-1.3%0.652.3%0.652.3%0.652.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.130.5%0.130.5%
Usd Total Gains Per Share-0.67-2.4%-0.36-1.3%0.652.3%0.782.8%0.782.8%
Usd Price Per Share45.21-39.60-68.05-53.98-53.98-
Price to Earnings Ratio-27.32-58.21-31.79-28.67-28.67-
Price-to-Total Gains Ratio-67.85--154.54-152.23-6.44-6.44-
Price to Book Ratio3.85-3.20-5.45-6.40-6.40-
Price-to-Total Gains Ratio-67.85--154.54-152.23-6.44-6.44-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share30.201044
Number of shares33
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.13
Usd Book Value Change Per Share-0.360.65
Usd Total Gains Per Share-0.360.78
Gains per Quarter (33 shares)-11.8925.74
Gains per Year (33 shares)-47.57102.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-48-58178693
20-95-10634172196
30-143-15451258299
40-190-20268344402
50-238-25085430505
60-285-298101516608
70-333-346118602711
80-381-394135688814
90-428-442152775917
100-476-4901698611020

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%16.02.00.088.9%16.02.00.088.9%16.02.00.088.9%
Book Value Change Per Share0.04.00.00.0%8.04.00.066.7%12.06.00.066.7%12.06.00.066.7%12.06.00.066.7%
Dividend per Share0.00.04.00.0%2.00.010.016.7%6.00.012.033.3%6.00.012.033.3%6.00.012.033.3%
Total Gains per Share0.04.00.00.0%8.04.00.066.7%12.06.00.066.7%12.06.00.066.7%12.06.00.066.7%

Fundamentals of Pharma Mar SAU

About Pharma Mar SAU

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Fundamental data was last updated by Penke on 2024-04-18 09:01:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Pharma Mar SAU.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pharma Mar SAU earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • A Net Profit Margin of -16.8% means that €-0.17 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharma Mar SAU:

  • The MRQ is -16.8%. The company is making a huge loss. -2
  • The TTM is 0.6%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ-16.8%TTM0.6%-17.4%
TTM0.6%YOY25.0%-24.5%
TTM0.6%5Y26.6%-26.0%
5Y26.6%10Y26.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.8%-207.2%+190.4%
TTM0.6%-216.8%+217.4%
YOY25.0%-282.3%+307.3%
5Y26.6%-436.8%+463.4%
10Y26.6%-597.3%+623.9%
1.1.2. Return on Assets

Shows how efficient Pharma Mar SAU is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • -2.0% Return on Assets means that Pharma Mar SAU generated €-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharma Mar SAU:

  • The MRQ is -2.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.1%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-2.0%TTM0.1%-2.1%
TTM0.1%YOY3.2%-3.2%
TTM0.1%5Y5.1%-5.0%
5Y5.1%10Y5.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.0%-13.3%+11.3%
TTM0.1%-12.8%+12.9%
YOY3.2%-11.6%+14.8%
5Y5.1%-13.8%+18.9%
10Y5.1%-15.6%+20.7%
1.1.3. Return on Equity

Shows how efficient Pharma Mar SAU is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • -3.5% Return on Equity means Pharma Mar SAU generated €-0.04 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharma Mar SAU:

  • The MRQ is -3.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 0.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-3.5%TTM0.1%-3.6%
TTM0.1%YOY6.0%-5.9%
TTM0.1%5Y20.8%-20.7%
5Y20.8%10Y20.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.5%-16.9%+13.4%
TTM0.1%-16.1%+16.2%
YOY6.0%-14.9%+20.9%
5Y20.8%-19.3%+40.1%
10Y20.8%-20.1%+40.9%

1.2. Operating Efficiency of Pharma Mar SAU.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharma Mar SAU is operating .

  • Measures how much profit Pharma Mar SAU makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharma Mar SAU:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY14.7%-14.7%
TTM-5Y23.4%-23.4%
5Y23.4%10Y23.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY14.7%-288.4%+303.1%
5Y23.4%-486.2%+509.6%
10Y23.4%-628.4%+651.8%
1.2.2. Operating Ratio

Measures how efficient Pharma Mar SAU is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.19 means that the operating costs are €1.19 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Pharma Mar SAU:

  • The MRQ is 1.186. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.094. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.186TTM1.094+0.092
TTM1.094YOY0.833+0.261
TTM1.0945Y0.825+0.269
5Y0.82510Y0.8250.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1863.235-2.049
TTM1.0943.310-2.216
YOY0.8333.838-3.005
5Y0.8255.679-4.854
10Y0.8257.823-6.998

1.3. Liquidity of Pharma Mar SAU.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharma Mar SAU is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.63 means the company has €2.63 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharma Mar SAU:

  • The MRQ is 2.634. The company is able to pay all its short-term debts. +1
  • The TTM is 2.918. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.634TTM2.918-0.283
TTM2.918YOY3.057-0.139
TTM2.9185Y2.684+0.234
5Y2.68410Y2.6840.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6343.863-1.229
TTM2.9184.169-1.251
YOY3.0575.337-2.280
5Y2.6846.122-3.438
10Y2.6846.434-3.750
1.3.2. Quick Ratio

Measures if Pharma Mar SAU is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • A Quick Ratio of 1.35 means the company can pay off €1.35 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharma Mar SAU:

  • The MRQ is 1.353. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.367. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.353TTM1.367-0.014
TTM1.367YOY0.933+0.434
TTM1.3675Y1.056+0.311
5Y1.05610Y1.0560.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3533.504-2.151
TTM1.3673.991-2.624
YOY0.9335.371-4.438
5Y1.0566.088-5.032
10Y1.0566.395-5.339

1.4. Solvency of Pharma Mar SAU.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharma Mar SAU assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharma Mar SAU to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.43 means that Pharma Mar SAU assets are financed with 43.2% credit (debt) and the remaining percentage (100% - 43.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharma Mar SAU:

  • The MRQ is 0.432. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.419. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.432TTM0.419+0.013
TTM0.419YOY0.452-0.034
TTM0.4195Y0.592-0.174
5Y0.59210Y0.5920.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4320.339+0.093
TTM0.4190.337+0.082
YOY0.4520.271+0.181
5Y0.5920.368+0.224
10Y0.5920.388+0.204
1.4.2. Debt to Equity Ratio

Measures if Pharma Mar SAU is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • A Debt to Equity ratio of 76.0% means that company has €0.76 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharma Mar SAU:

  • The MRQ is 0.760. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.721. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.760TTM0.721+0.040
TTM0.721YOY0.827-0.107
TTM0.7215Y1.754-1.033
5Y1.75410Y1.7540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7600.392+0.368
TTM0.7210.403+0.318
YOY0.8270.335+0.492
5Y1.7540.427+1.327
10Y1.7540.461+1.293

2. Market Valuation of Pharma Mar SAU

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Pharma Mar SAU generates.

  • Above 15 is considered overpriced but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • A PE ratio of -27.32 means the investor is paying €-27.32 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharma Mar SAU:

  • The EOD is -18.250. Based on the earnings, the company is expensive. -2
  • The MRQ is -27.317. Based on the earnings, the company is expensive. -2
  • The TTM is 58.214. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-18.250MRQ-27.317+9.067
MRQ-27.317TTM58.214-85.532
TTM58.214YOY31.792+26.423
TTM58.2145Y28.666+29.549
5Y28.66610Y28.6660.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-18.250-2.300-15.950
MRQ-27.317-2.656-24.661
TTM58.214-2.718+60.932
YOY31.792-4.145+35.937
5Y28.666-6.258+34.924
10Y28.666-6.315+34.981
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharma Mar SAU:

  • The EOD is -14.833. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -22.202. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.850. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.833MRQ-22.202+7.369
MRQ-22.202TTM-3.850-18.352
TTM-3.850YOY-45.685+41.835
TTM-3.8505Y-89.062+85.211
5Y-89.06210Y-89.0620.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-14.833-2.974-11.859
MRQ-22.202-3.306-18.896
TTM-3.850-3.508-0.342
YOY-45.685-5.613-40.072
5Y-89.062-8.378-80.684
10Y-89.062-8.873-80.189
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharma Mar SAU is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.85 means the investor is paying €3.85 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharma Mar SAU:

  • The EOD is 2.573. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.852. Based on the equity, the company is fair priced.
  • The TTM is 3.201. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.573MRQ3.852-1.279
MRQ3.852TTM3.201+0.651
TTM3.201YOY5.452-2.252
TTM3.2015Y6.402-3.202
5Y6.40210Y6.4020.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.5731.914+0.659
MRQ3.8522.116+1.736
TTM3.2012.097+1.104
YOY5.4522.881+2.571
5Y6.4023.550+2.852
10Y6.4023.936+2.466
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Pharma Mar SAU compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.623-0.337-46%0.609-202%0.609-202%0.609-202%
Book Value Per Share--10.96611.581-5%11.688-6%8.115+35%8.115+35%
Current Ratio--2.6342.918-10%3.057-14%2.684-2%2.684-2%
Debt To Asset Ratio--0.4320.419+3%0.452-4%0.592-27%0.592-27%
Debt To Equity Ratio--0.7600.721+5%0.827-8%1.754-57%1.754-57%
Dividend Per Share----0%-0%0.120-100%0.120-100%
Eps---0.3870.014-2818%0.650-159%0.876-144%0.876-144%
Free Cash Flow Per Share---0.476-0.413-13%0.409-216%0.840-157%0.840-157%
Free Cash Flow To Equity Per Share---0.476-0.413-13%0.498-196%0.552-186%0.552-186%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---51.685--------
Intrinsic Value_10Y_min---42.777--------
Intrinsic Value_1Y_max---0.474--------
Intrinsic Value_1Y_min---0.462--------
Intrinsic Value_3Y_max---5.009--------
Intrinsic Value_3Y_min---4.710--------
Intrinsic Value_5Y_max---13.868--------
Intrinsic Value_5Y_min---12.564--------
Market Cap494072938.000-51%745109671.680660168440.690+13%1147878242.135-35%911230415.011-18%911230415.011-18%
Net Profit Margin---0.1680.006-3089%0.250-167%0.266-163%0.266-163%
Operating Margin----0%0.147-100%0.234-100%0.234-100%
Operating Ratio--1.1861.094+8%0.833+42%0.825+44%0.825+44%
Pb Ratio2.573-50%3.8523.201+20%5.452-29%6.402-40%6.402-40%
Pe Ratio-18.250+33%-27.31758.214-147%31.792-186%28.666-195%28.666-195%
Price Per Share28.220-50%42.24037.005+14%63.585-34%50.441-16%50.441-16%
Price To Free Cash Flow Ratio-14.833+33%-22.202-3.850-83%-45.685+106%-89.062+301%-89.062+301%
Price To Total Gains Ratio-45.328+33%-67.847-154.537+128%152.230-145%6.443-1153%6.443-1153%
Quick Ratio--1.3531.367-1%0.933+45%1.056+28%1.056+28%
Return On Assets---0.0200.001-3896%0.032-162%0.051-139%0.051-139%
Return On Equity---0.0350.001-5698%0.060-159%0.208-117%0.208-117%
Total Gains Per Share---0.623-0.337-46%0.609-202%0.729-185%0.729-185%
Usd Book Value--207017347.600221227998.300-6%225865174.900-8%156639525.722+32%156639525.722+32%
Usd Book Value Change Per Share---0.666-0.360-46%0.651-202%0.652-202%0.652-202%
Usd Book Value Per Share--11.73612.394-5%12.509-6%8.685+35%8.685+35%
Usd Dividend Per Share----0%-0%0.128-100%0.128-100%
Usd Eps---0.4140.015-2818%0.696-159%0.938-144%0.938-144%
Usd Free Cash Flow---8978978.000-7866505.100-12%7884430.950-214%16613368.611-154%16613368.611-154%
Usd Free Cash Flow Per Share---0.509-0.442-13%0.438-216%0.899-157%0.899-157%
Usd Free Cash Flow To Equity Per Share---0.509-0.442-13%0.533-196%0.590-186%0.590-186%
Usd Market Cap528756858.248-51%797416370.632706512265.226+13%1228459294.733-35%975198790.145-18%975198790.145-18%
Usd Price Per Share30.201-50%45.20539.603+14%68.049-34%53.982-16%53.982-16%
Usd Profit---7297693.800304204.350-2499%13205197.800-155%17275049.489-142%17275049.489-142%
Usd Revenue--43353802.00042313835.150+2%52531569.650-17%53432767.233-19%53432767.233-19%
Usd Total Gains Per Share---0.666-0.360-46%0.651-202%0.780-185%0.780-185%
 EOD+3 -5MRQTTM+7 -25YOY+6 -275Y+9 -2610Y+9 -26

3.2. Fundamental Score

Let's check the fundamental score of Pharma Mar SAU based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-18.250
Price to Book Ratio (EOD)Between0-12.573
Net Profit Margin (MRQ)Greater than0-0.168
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.353
Current Ratio (MRQ)Greater than12.634
Debt to Asset Ratio (MRQ)Less than10.432
Debt to Equity Ratio (MRQ)Less than10.760
Return on Equity (MRQ)Greater than0.15-0.035
Return on Assets (MRQ)Greater than0.05-0.020
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Pharma Mar SAU based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose28.220
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Income  5,984-4,5731,4113,6135,024-3,5031,521-8,340-6,819
Net Income from Continuing Operations  1,389221,4113,6135,024-3,5031,521-8,340-6,819



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets340,520
Total Liabilities147,082
Total Stockholder Equity193,438
 As reported
Total Liabilities 147,082
Total Stockholder Equity+ 193,438
Total Assets = 340,520

Assets

Total Assets340,520
Total Current Assets252,602
Long-term Assets87,918
Total Current Assets
Cash And Cash Equivalents 60,024
Short-term Investments 102,538
Net Receivables 27,203
Inventory 39,289
Other Current Assets 14,067
Total Current Assets  (as reported)252,602
Total Current Assets  (calculated)243,121
+/- 9,481
Long-term Assets
Property Plant Equipment 47,607
Intangible Assets 1,935
Long-term Assets  (as reported)87,918
Long-term Assets  (calculated)49,542
+/- 38,376

Liabilities & Shareholders' Equity

Total Current Liabilities95,888
Long-term Liabilities51,194
Total Stockholder Equity193,438
Total Current Liabilities
Short Long Term Debt 12,825
Accounts payable 29,174
Other Current Liabilities 15,840
Total Current Liabilities  (as reported)95,888
Total Current Liabilities  (calculated)57,839
+/- 38,049
Long-term Liabilities
Long term Debt 27,036
Capital Lease Obligations Min Short Term Debt3,808
Long-term Liabilities Other 193
Long-term Liabilities  (as reported)51,194
Long-term Liabilities  (calculated)31,037
+/- 20,157
Total Stockholder Equity
Retained Earnings 142,223
Total Stockholder Equity (as reported)193,438
Total Stockholder Equity (calculated)142,223
+/- 51,215
Other
Capital Stock11,013
Common Stock Shares Outstanding 17,640
Net Invested Capital 233,299
Net Working Capital 156,714
Property Plant and Equipment Gross 94,525



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
112,537
124,705
275,611
352,227
329,731
330,259
345,102
342,542
347,692
368,386
378,028
390,772
379,098
393,259
373,717
358,690
349,412
340,520
340,520349,412358,690373,717393,259379,098390,772378,028368,386347,692342,542345,102330,259329,731352,227275,611124,705112,537
   > Total Current Assets 
50,751
49,976
202,583
259,470
237,859
245,651
261,420
276,683
280,941
295,231
289,149
274,689
265,939
275,183
257,475
267,839
260,973
252,602
252,602260,973267,839257,475275,183265,939274,689289,149295,231280,941276,683261,420245,651237,859259,470202,58349,97650,751
       Cash And Cash Equivalents 
23,409
17,638
153,992
208,892
93,222
96,210
106,432
129,587
132,167
113,348
152,255
142,723
129,433
149,813
119,711
76,070
69,975
60,024
60,02469,97576,070119,711149,813129,433142,723152,255113,348132,167129,587106,43296,21093,222208,892153,99217,63823,409
       Short-term Investments 
3,597
3,257
19,612
19,214
104,023
99,306
103,627
87,145
88,947
88,532
69,333
53,973
56,917
32,607
63,416
108,826
104,378
102,538
102,538104,378108,82663,41632,60756,91753,97369,33388,53288,94787,145103,62799,306104,02319,21419,6123,2573,597
       Net Receivables 
11,682
11,530
16,793
18,247
27,452
24,054
26,850
27,853
26,036
50,908
30,801
32,320
29,154
29,328
24,447
25,936
30,182
27,203
27,20330,18225,93624,44729,32829,15432,32030,80150,90826,03627,85326,85024,05427,45218,24716,79311,53011,682
       Inventory 
8,541
8,902
8,725
9,576
8,574
11,933
8,722
10,744
10,539
10,536
15,733
18,590
21,507
27,746
32,618
35,559
34,892
39,289
39,28934,89235,55932,61827,74621,50718,59015,73310,53610,53910,7448,72211,9338,5749,5768,7258,9028,541
       Other Current Assets 
3,522
7,314
3,461
3,541
4,588
13,151
15,789
21,354
23,252
27,999
21,027
27,083
28,928
29,709
17,283
20,896
21,546
14,067
14,06721,54620,89617,28329,70928,92827,08321,02727,99923,25221,35415,78913,1514,5883,5413,4617,3143,522
   > Long-term Assets 
61,786
74,729
73,028
92,757
91,872
84,608
83,681
65,859
66,751
73,155
88,879
116,083
113,159
118,076
116,242
90,851
88,439
87,918
87,91888,43990,851116,242118,076113,159116,08388,87973,15566,75165,85983,68184,60891,87292,75773,02874,72961,786
       Property Plant Equipment 
0
25,602
24,985
25,118
24,990
24,745
26,753
27,180
28,745
26,896
30,639
30,077
27,688
34,715
34,148
39,186
43,006
47,607
47,60743,00639,18634,14834,71527,68830,07730,63926,89628,74527,18026,75324,74524,99025,11824,98525,6020
       Intangible Assets 
3,949
6,074
5,287
4,785
0
3,860
0
0
0
3,233
0
0
0
2,589
0
0
0
1,935
1,9350002,5890003,2330003,86004,7855,2876,0743,949
       Long-term Assets Other 
1
0
1
1
1
0
1
0
0
0
0
0
0
0
0
0
0
0
000000000001011101
> Total Liabilities 
121,746
117,249
198,229
248,729
231,581
227,537
217,577
207,688
204,487
190,468
176,227
183,836
166,594
170,302
156,786
148,388
143,217
147,082
147,082143,217148,388156,786170,302166,594183,836176,227190,468204,487207,688217,577227,537231,581248,729198,229117,249121,746
   > Total Current Liabilities 
60,768
60,439
103,758
108,447
105,723
94,919
83,793
77,334
81,444
86,346
80,648
96,087
89,940
97,320
89,029
85,509
86,625
95,888
95,88886,62585,50989,02997,32089,94096,08780,64886,34681,44477,33483,79394,919105,723108,447103,75860,43960,768
       Short Long Term Debt 
28,722
29,655
17,004
18,524
17,051
15,313
16,235
16,152
14,368
12,212
12,183
10,736
13,776
13,125
13,213
12,748
12,777
12,825
12,82512,77712,74813,21313,12513,77610,73612,18312,21214,36816,15216,23515,31317,05118,52417,00429,65528,722
       Accounts payable 
19,198
16,471
15,002
15,170
15,987
21,039
20,696
13,625
19,160
26,928
26,353
24,689
31,117
27,492
21,075
23,134
21,284
29,174
29,17421,28423,13421,07527,49231,11724,68926,35326,92819,16013,62520,69621,03915,98715,17015,00216,47119,198
       Other Current Liabilities 
2,406
4,974
64,440
68,700
64,522
48,310
40,891
40,775
38,512
35,884
35,483
53,223
35,326
44,383
23,187
16,105
17,351
15,840
15,84017,35116,10523,18744,38335,32653,22335,48335,88438,51240,77540,89148,31064,52268,70064,4404,9742,406
   > Long-term Liabilities 
60,978
56,810
109,473
140,283
125,858
132,618
133,784
130,354
123,043
104,122
95,579
87,749
76,654
72,982
67,757
62,879
56,592
51,194
51,19456,59262,87967,75772,98276,65487,74995,579104,122123,043130,354133,784132,618125,858140,283109,47356,81060,978
       Long term Debt 
56,897
53,063
43,554
40,927
39,865
37,732
34,132
37,160
36,352
33,386
31,417
30,291
26,059
25,883
26,562
27,060
26,873
27,036
27,03626,87327,06026,56225,88326,05930,29131,41733,38636,35237,16034,13237,73239,86540,92743,55453,06356,897
       Capital Lease Obligations Min Short Term Debt
3,708
3,397
3,076
3,390
3,357
3,620
4,021
3,919
3,784
3,735
4,097
3,593
2,583
3,622
3,613
3,870
3,928
3,808
3,8083,9283,8703,6133,6222,5833,5934,0973,7353,7843,9194,0213,6203,3573,3903,0763,3973,708
       Other Liabilities 
0
2,028
49,399
97,457
84,209
92,736
97,382
91,073
84,698
68,820
62,219
55,871
49,369
45,085
0
0
0
0
000045,08549,36955,87162,21968,82084,69891,07397,38292,73684,20997,45749,3992,0280
       Long-term Liabilities Other 
177
177
15,174
174
175
176
177
178
182
186
188
184
184
186
189
191
191
193
19319119118918618418418818618217817717617517415,174177177
       Deferred Long Term Liability 
0
5,151
0
0
0
2,807
0
0
0
2,105
0
0
0
1,403
0
0
0
0
00001,4030002,1050002,8070005,1510
> Total Stockholder Equity
-5,296
11,374
81,304
107,434
98,150
102,722
127,525
134,854
143,205
177,918
201,801
206,936
212,504
222,957
216,931
210,302
206,195
193,438
193,438206,195210,302216,931222,957212,504206,936201,801177,918143,205134,854127,525102,72298,150107,43481,30411,374-5,296
   Common Stock
0
11,132
11,132
11,132
11,132
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
0
0
0
0
000011,01311,01311,01311,01311,01311,01311,01311,01311,01311,13211,13211,13211,1320
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
0
15
11
14
14
14
16
16
17
19
20
21
22
19
0
0
0
0
0000192221201917161614141411150



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue158,153
Cost of Revenue-9,613
Gross Profit148,540148,540
 
Operating Income (+$)
Gross Profit148,540
Operating Expense-162,251
Operating Income-4,098-13,711
 
Operating Expense (+$)
Research Development99,302
Selling General Administrative41,805
Selling And Marketing Expenses0
Operating Expense162,251141,107
 
Net Interest Income (+$)
Interest Income4,103
Interest Expense-2,416
Other Finance Cost-0
Net Interest Income1,687
 
Pretax Income (+$)
Operating Income-4,098
Net Interest Income1,687
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-3,623-4,098
EBIT - interestExpense = -2,416
1,137
3,553
Interest Expense2,416
Earnings Before Interest and Taxes (EBIT)0-1,207
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-3,623
Tax Provision--4,760
Net Income From Continuing Ops1,1371,137
Net Income1,137
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-1,687
 

Technical Analysis of Pharma Mar SAU
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pharma Mar SAU. The general trend of Pharma Mar SAU is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pharma Mar SAU's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pharma Mar SAU.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 27.66 < 28.40 < 29.44.

The bearish price targets are: .

Tweet this
Pharma Mar SAU Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pharma Mar SAU. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pharma Mar SAU Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pharma Mar SAU.

Pharma Mar SAU Daily Moving Average Convergence/Divergence (MACD) ChartPharma Mar SAU Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pharma Mar SAU. The current adx is .

Pharma Mar SAU Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pharma Mar SAU.

Pharma Mar SAU Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pharma Mar SAU.

Pharma Mar SAU Daily Relative Strength Index (RSI) ChartPharma Mar SAU Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pharma Mar SAU.

Pharma Mar SAU Daily Stochastic Oscillator ChartPharma Mar SAU Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pharma Mar SAU.

Pharma Mar SAU Daily Commodity Channel Index (CCI) ChartPharma Mar SAU Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pharma Mar SAU.

Pharma Mar SAU Daily Chande Momentum Oscillator (CMO) ChartPharma Mar SAU Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pharma Mar SAU.

Pharma Mar SAU Daily Williams %R ChartPharma Mar SAU Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pharma Mar SAU.

Pharma Mar SAU Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pharma Mar SAU.

Pharma Mar SAU Daily Average True Range (ATR) ChartPharma Mar SAU Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pharma Mar SAU.

Pharma Mar SAU Daily On-Balance Volume (OBV) ChartPharma Mar SAU Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pharma Mar SAU.

Pharma Mar SAU Daily Money Flow Index (MFI) ChartPharma Mar SAU Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pharma Mar SAU.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-02 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-19 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-18 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-24 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Pharma Mar SAU Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pharma Mar SAU based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose28.220
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pharma Mar SAU with someone you think should read this too:
  • Are you bullish or bearish on Pharma Mar SAU? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pharma Mar SAU? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pharma Mar SAU

I send you an email if I find something interesting about Pharma Mar SAU.


Comments

How you think about this?

Leave a comment

Stay informed about Pharma Mar SAU.

Receive notifications about Pharma Mar SAU in your mailbox!